Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240043/S001

DIAM Spinal Stabilization System

Companion Spine France Sas · Decision date Apr 1, 2026

FDA DECISIONP240043/S001

What did the FDA approve?

FDA records P240043/S001 as a supplement to PMA P240043, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 1, 2026.

FDA approval order statement

Approval for a shelf-life extension from 1-year to 5-years for the DIAM Spinal Stabilization System. Based upon the information submitted, the PMA supplement is approved.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Orthopedic
Decision date
Apr 1, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P240043/S001
Regulatory pathway
PMA supplement
Product code
NQO
Decision code
APPR
Decision date
Apr 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, spinous process spacer/plate.

Product code
NQO
FDA device class
3

For the original device and its historical approval scope, see PMA P240043. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240043 · Original PMA

    DIAM Spinal Stabilization System

  2. P240043/S001 received

    Application receipt date recorded by FDA.

  3. P240043/S001 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240043

Product / regulatory recordCompanyPathwayDecision dateSource
Companion Spine France SasPMA approvalDec 10, 2025FDA

Explore the linked device profile

Other records with product code NQO

Product / regulatory recordCompanyPathwayDecision dateSource
Companion Spine FrancePMA supplementMay 22, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Companion Spine France Sas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Immeuble Le Bridge 5, 5 Allee Des Acacias, Merignac, 33 700

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records